Okunlola Ayoyimika O, Ajao Temitope O, Sabi Mwila, Kolawole Olayinka D, Eweka Osasere A, Karim Abbas, Adebayo Toluwani E
Internal Medicine, United Lincolnshire Hospitals NHS trust, Lincolnshire, GBR.
General and Acute Medicine, United Lincolnshire Hospitals NHS Trust, Lincolnshire, GBR.
Cureus. 2024 Sep 19;16(9):e69730. doi: 10.7759/cureus.69730. eCollection 2024 Sep.
Antiphospholipid syndrome (APS) is an autoimmune disorder characterized by blood clots and pregnancy complications due to antiphospholipid antibodies. Catastrophic APS (CAPS), a severe variant, leads to multiorgan failure and is often fatal. Pathogenesis involves antiphospholipid antibodies, particularly anti-beta-2-glycoprotein I (aβ2GPI), which trigger endothelial cell (EC) activation, cytokine release, and a prothrombotic state. Infections, surgeries, and other triggers can precipitate CAPS, leading to widespread microthromboses and systemic inflammatory responses. CAPS predominantly affects younger patients and those with systemic lupus erythematosus (SLE), with a high mortality rate, though recent treatment advances have improved survival. Diagnosing CAPS involves identifying clinical manifestations, including rapid organ involvement and small vessel occlusions, confirmed by histopathology and high antiphospholipid antibody levels. The CAPS registry data indicate that commonly affected organs include kidneys, lungs, central nervous system, and the heart, with a high prevalence of lupus anticoagulant and anticardiolipin antibodies (aCL). Current management strategies focus on therapeutic anticoagulation, immunosuppressive therapies like corticosteroids, and adjunct treatments such as plasmapheresis and intravenous immunoglobulin (IVIG). Early use of glucocorticoids and combination therapy has significantly improved outcomes. In life-threatening cases, especially with microangiopathy, experts recommend performing plasma exchange (PE). Patients with associated autoimmune conditions or refractory cases may receive cyclophosphamide (CY) and rituximab while considering PE for treatment. Maintenance of anticoagulation with an appropriate international normalized ratio (INR) is crucial to prevent recurrence. This article reviews the pathogenesis and epidemiology of CAPS. It also examines the current management strategies, and discusses the challenges and controversies associated with these strategies. It hereafter offers recommendations for future management and outlines directions for further research.
抗磷脂综合征(APS)是一种自身免疫性疾病,其特征是由于抗磷脂抗体导致血栓形成和妊娠并发症。灾难性抗磷脂综合征(CAPS)是一种严重的变体,可导致多器官功能衰竭,且往往是致命的。发病机制涉及抗磷脂抗体,尤其是抗β2糖蛋白I(aβ2GPI),它会触发内皮细胞(EC)活化、细胞因子释放和血栓前状态。感染、手术和其他诱因可引发CAPS,导致广泛的微血栓形成和全身炎症反应。CAPS主要影响年轻患者和系统性红斑狼疮(SLE)患者,死亡率很高,不过最近的治疗进展提高了生存率。诊断CAPS需要识别临床表现,包括快速的器官受累和小血管闭塞,并通过组织病理学和高抗磷脂抗体水平得到证实。CAPS登记数据表明,常见受累器官包括肾脏、肺、中枢神经系统和心脏,狼疮抗凝物和抗心磷脂抗体(aCL)的患病率很高。当前的管理策略侧重于治疗性抗凝、如皮质类固醇的免疫抑制疗法以及诸如血浆置换和静脉注射免疫球蛋白(IVIG)的辅助治疗。早期使用糖皮质激素和联合治疗显著改善了治疗效果。在危及生命的病例中,尤其是伴有微血管病的病例,专家建议进行血浆置换(PE)。患有相关自身免疫性疾病或难治性病例的患者在考虑进行PE治疗时可能会接受环磷酰胺(CY)和利妥昔单抗治疗。维持适当的国际标准化比值(INR)进行抗凝对于预防复发至关重要。本文综述了CAPS的发病机制和流行病学。它还研究了当前的管理策略,并讨论了与这些策略相关的挑战和争议。此后,它为未来的管理提供了建议,并概述了进一步研究的方向。